CA2545443A1 - Solid amorphous dispersions of an mtp inhibitor for treatment of obesity - Google Patents

Solid amorphous dispersions of an mtp inhibitor for treatment of obesity Download PDF

Info

Publication number
CA2545443A1
CA2545443A1 CA002545443A CA2545443A CA2545443A1 CA 2545443 A1 CA2545443 A1 CA 2545443A1 CA 002545443 A CA002545443 A CA 002545443A CA 2545443 A CA2545443 A CA 2545443A CA 2545443 A1 CA2545443 A1 CA 2545443A1
Authority
CA
Canada
Prior art keywords
solid amorphous
dispersion
drug
amorphous dispersion
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002545443A
Other languages
English (en)
French (fr)
Inventor
Dwayne Thomas Friesen
Ravi Mysore Shanker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2545443A1 publication Critical patent/CA2545443A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Indole Compounds (AREA)
CA002545443A 2003-11-14 2004-11-01 Solid amorphous dispersions of an mtp inhibitor for treatment of obesity Abandoned CA2545443A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51993103P 2003-11-14 2003-11-14
US60/519,931 2003-11-14
PCT/IB2004/003581 WO2005046644A1 (en) 2003-11-14 2004-11-01 Solid amorphous dispersions of an mtp inhibitor for treatment of obesity

Publications (1)

Publication Number Publication Date
CA2545443A1 true CA2545443A1 (en) 2005-05-26

Family

ID=34590458

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002545443A Abandoned CA2545443A1 (en) 2003-11-14 2004-11-01 Solid amorphous dispersions of an mtp inhibitor for treatment of obesity

Country Status (16)

Country Link
US (1) US20080293801A1 (https=)
EP (1) EP1696887A1 (https=)
JP (1) JP2007511500A (https=)
KR (1) KR20060096076A (https=)
CN (1) CN1878538A (https=)
AR (1) AR048206A1 (https=)
AU (1) AU2004289110A1 (https=)
BR (1) BRPI0416596A (https=)
CA (1) CA2545443A1 (https=)
CO (1) CO5690536A2 (https=)
IL (1) IL175372A0 (https=)
MX (1) MXPA06005489A (https=)
NO (1) NO20062778L (https=)
NZ (1) NZ546677A (https=)
TW (1) TW200515909A (https=)
WO (1) WO2005046644A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE449776T1 (de) 2005-12-15 2009-12-15 Hoffmann La Roche Pyrroloä2,3-cüpyridinderivate
WO2008090198A1 (en) * 2007-01-25 2008-07-31 Janssen Pharmaceutica Nv Use of mtp inhibitors for increasing levels of satiety hormones
CN102781914B (zh) * 2010-01-06 2014-09-17 武田药品工业株式会社 吲哚衍生物
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
EP3861989A1 (en) * 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
US12453728B1 (en) 2024-08-08 2025-10-28 Redux Therapeutics, Llc Compositions comprising inhibitors of microsomal triglyceride transfer protein and Apo-B secretion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4884235A (en) * 1988-07-19 1989-11-28 Thiele Alfred A Micromagnetic memory package
KR0182801B1 (ko) * 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
DE19504832A1 (de) * 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
SK287806B6 (sk) * 2001-06-28 2011-10-04 Pfizer Products Inc. Triamid-substituované indoly, benzofurány a benzotiofény ako inhibítory mikrozómového proteínu prenášajúceho triglyceridu (MTP) a/alebo sekrécie apolipoproteínu B (Apo B)
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo

Also Published As

Publication number Publication date
CO5690536A2 (es) 2006-10-31
AU2004289110A1 (en) 2005-05-26
JP2007511500A (ja) 2007-05-10
EP1696887A1 (en) 2006-09-06
NO20062778L (no) 2006-08-14
BRPI0416596A (pt) 2007-01-30
KR20060096076A (ko) 2006-09-05
MXPA06005489A (es) 2006-08-11
IL175372A0 (en) 2006-09-05
CN1878538A (zh) 2006-12-13
TW200515909A (en) 2005-05-16
US20080293801A1 (en) 2008-11-27
AR048206A1 (es) 2006-04-12
NZ546677A (en) 2008-11-28
WO2005046644A1 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
EP2101741B1 (en) Solid dispersion comprising a poorly water soluble drug
EP0901786B1 (en) Solid pharmaceutical dispersions with enhanced bioavailability
US9387252B2 (en) Pharmaceutical compositions with enhanced performance
KR20120101439A (ko) 프로페인-1-설폰산 ｛3-〔5-(4-클로로-페닐)-1ｈ-피롤로〔2,3-ｂ〕피리딘-3-카보닐〕-2,4-다이플루오로-페닐｝-아마이드 조성물 및 그의 용도
TW201414469A (zh) 對包括ｖｘ-９５０之藥物實施噴霧乾燥之方法及由此方法製備之產物
TWI729476B (zh) 纖維素粉末、其用途及錠劑
WO2008043167A1 (en) Pharmaceutical compositions comprising intra- and extra- granular fractions
EP1741424B1 (en) Solid pharmaceutical dispersions with enhanced bioavailabilty
WO2008076780A2 (en) Amorphous valsartan and the production thereof
WO2023168316A1 (en) Enteric coated dry powdered cannabinoid formulations
CA2867701C (en) Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles
US20080293801A1 (en) Solid Amorphous Dispersions of An Mtp Inhibitor For Treatment of Obesity
JP7028927B2 (ja) 顆粒の静電量を低減させる方法
MX2007005427A (es) Composicion de dispersion solida de pranlukast con biodisponibilidad mejorada y metodo para preparar la dispersion solida.
CN113318097A (zh) 一种抗特发性肺纤维化的粉雾剂及制备方法
US20090264476A1 (en) CB-1 receptor modulator formulations
HK1094533A (en) Solid amorphous dispersions of an mtp inhibitor for treatment of obesity
KR20240014049A (ko) 아프레밀라스트의 제형
JPH04368330A (ja) ペミロラストカリウムの徐放性製剤
CN120617184A (zh) 一种高口服生物利用度氟苯尼考制剂制备方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued